The shady side of dasatinib.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Senotherapeutic Potential of Araliadiol in Senescent Human Dermal Fibroblasts: An In Vitro Study Using Three Senescence Models.Pharmaceutics · 2025
   Article
2. Development of molecular and pharmacological switches for chimeric antigen receptor T cells.Experimental hematology & oncology · 2019
   Article
3. Src-dependent phosphorylation of μ-opioid receptor at TyrEMBO molecular medicine · 2017
   Article
4. Treatment recommendations for chronic myeloid leukemia.Mediterranean journal of hematology and infectious diseases · 2014
   Review
5. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Blood · 2013
   Review
6. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.Investigational new drugs · 2013
   Article

Corrections and comments

• Comment on
  Dasatinib inhibits proinflammatory functions of mature human neutrophils.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as